BioAlliance Pharma will participate in BioPartnering EuropeTM Conference (London, 10-12 October, 2010)

BioAlliance Pharma SA (Euronext Paris -BIO), a company dedicated to the supportive care and treatment of cancer patients, will participate in the 18th BioPartnering EuropeTM Conference (London, 10-12 October, 2010). This international annual conference is dedicated to meetings between the various players in the pharma/biotech area.
BioAlliance’s management team will present its development strategy and the significant advances that were recently achieved. It will notably emphasize on the results and prospects of acyclovir Lauriad®, a product developed for the treatment of recurrent herpes labialis whose registration file submission is planned in 2011 in Europe and in the United States.

101005EN_BioPartnering Europe